Ampliphi Biosciences Corp (NYSE:APHB) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price target of $4.00 for the company and are predicting that the company will post ($0.80) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Ampliphi Biosciences Corp an industry rank of 108 out of 265 based on the ratings given to related companies.

Shares of Ampliphi Biosciences Corp (NYSE:APHB) opened at 0.83 on Tuesday. Ampliphi Biosciences Corp has a 12-month low of $0.67 and a 12-month high of $21.70. The company has a 50-day moving average price of $1.96 and a 200 day moving average price of $1.02. The company’s market capitalization is $5.50 million.

TRADEMARK VIOLATION NOTICE: “Analysts Expect Ampliphi Biosciences Corp (APHB) to Announce ($0.80) Earnings Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at

Ampliphi Biosciences Corp Company Profile

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Get a free copy of the Zacks research report on Ampliphi Biosciences Corp (APHB)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with's FREE daily email newsletter.